Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ARS Pharmaceuticals Inc SPRY

Healthcare Biotechnology
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and... see more

Recent & Breaking News (NDAQ:SPRY)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

PR Newswire December 13, 2021

Silverback Deadline Alert

Newsfile December 13, 2021

Silverback Update

Newsfile December 12, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

Newsfile December 11, 2021

Silverback Class Action Reminder

Newsfile December 9, 2021

Silverback Shareholder Notice

Newsfile December 8, 2021

Silverback Shareholder Alert

Newsfile December 7, 2021

UPCOMING DEADLINE: Silverback Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile December 7, 2021

Silverback Deadline Alert

Newsfile December 6, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Silverback Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2022 - SBTX

PR Newswire December 6, 2021

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Silverback Therapeutics, Inc. Investors With Losses Over $100K to Secure Counsel Before Important January 4 Deadline in Securities Class Action - SBTX

PR Newswire December 5, 2021

SBTX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 4, 2022 in the Class Action Filed on Behalf of Silverback Therapeutics, Inc. Limited Shareholders

Newsfile December 5, 2021

Silverback Update

Newsfile December 5, 2021

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile December 3, 2021

SBTX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Silverback Therapeutics, Inc.

Newsfile December 3, 2021

SBTX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 4, 2022 in the Class Action Filed on Behalf of Silverback Therapeutics, Inc. Limited Shareholders

Newsfile December 3, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

PR Newswire December 2, 2021

Silverback Class Action Reminder

Newsfile December 2, 2021

SBTX Loss Alert: Rosen, a Leading Law Firm, Encourages Silverback Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SBTX

Newsfile December 2, 2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Silverback Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2022 - (SBTX)

Newsfile December 2, 2021